Blueprint CEO Bryan Johnson defends blood plasma transfusion with son
news article · 2023
LINK
SUMMARY
Fortune report (byline Erin Prater, published 13 July 2023, 4:41pm ET; byline and date confirmed on the fetched page) on Johnson's July 2023 discontinuation of his young-plasma exchange regimen, which had included a one-liter plasma donation from his then-17-year-old son. Reproduces Johnson's own 5 July 2023 tweet: 'Discontinuing therapy: completed 6, 1L young plasma exchanges. 1x/mo (1 w/ my son). Evaluated biomarkers from biofluids, devices and imaging, no benefits detected.' Also reports that the procedure was 'approved by his team of 30 doctors' and was intended to reduce age-related brain decline.
NOTES
This article is the case’s primary account of the plasma-exchange claim and its self-disconfirmation: Johnson’s own words, reproduced in a dated, bylined news source, state plainly that a documented biomarker evaluation found no benefit, prompting discontinuation.